Blog

Cerillion plc (LSE:CER) has posted another year of strong financial performance, reporting a 4% rise in revenue to £45.4 million and a 10% increase in adjusted profit before tax to £21.8 million for the year ended 30 September 2025. The company also achieved record levels across several key metrics, including an adjusted EBITDA margin of 50.9% and a 25% jump in new orders to £47.6 million. Continued investment in R&D—particularly in AI capabilities—and expansion of operational teams have further reinforced Cerillion’s strategic position. Entering the new financial year, the company holds a sizeable back-order book and maintains a healthy sales pipeline, underscoring its strong market footing and future growth potential.

The company’s outlook is anchored by its solid financial results, which highlight sustained growth and profitability. Nonetheless, technical indicators point to pockets of near-term softness, and valuation levels appear elevated, potentially limiting immediate upside. With no additional earnings-call or corporate-event data available, these do not factor into the assessment.

More about Cerillion

Cerillion plc provides billing, charging, and CRM software solutions to telecommunications operators and, increasingly, to customers in utilities and financial services. Established over 26 years ago, the company supports around 70 installations across 45 countries. It is headquartered in London with operations in India and Bulgaria and maintains a global sales presence spanning Belgium, the U.S., Singapore, and Australia.

TT Electronics (LSE:TTG) has reported steady trading for the July–October 2025 period, posting revenue of £150.4 million—broadly in line with expectations. While its European operations continued to perform well, the company remains exposed to softer conditions in its EMS and Components divisions, driven by wider macroeconomic uncertainty. The board has reaffirmed its full-year profit guidance but cautioned that stronger execution will be required in the final months of 2025, particularly following the closure of the Plano site. Looking ahead, TT Electronics expects trading in 2026 to broadly resemble 2025, excluding non-recurring benefits, and is preparing further cost-reduction measures to navigate ongoing market volatility.

The company’s outlook is shaped by persistent financial pressures, including declining revenue trends and margin challenges. By contrast, technical indicators point to pockets of bullish momentum. Valuation headwinds remain, with negative earnings and the absence of dividends weighing on sentiment. Recent earnings commentary highlights regional disparities and ongoing restructuring efforts, which may support longer-term competitiveness even as they temper near-term expectations.

More about TT Electronics

TT Electronics is a global designer and manufacturer of engineered electronic components used in performance-critical environments. Serving industrial, medical, aerospace, and defence customers, the company provides sensors, power management technologies, and connectivity solutions. It operates design and manufacturing sites across the UK, North America, and Asia.

Microlise Group Plc (LSE:SAAS) has issued a trading update indicating that FY25 revenue is now expected to fall short of market forecasts, pressured by weaker order volumes from major global OEM partners and delays on several UK projects. Even so, the company projects annual recurring revenue to rise by about 4.5% and is preparing a series of cost-saving measures aimed at protecting margins and improving overall profitability. Microlise has also appointed Dean Garvey-North as its new Chief Technology Officer, a move intended to sharpen the company’s technology roadmap and strengthen alignment with long-term commercial goals. Management remains confident in the business’s growth trajectory, pointing to its resilient recurring revenue base and updated go-to-market strategy.

While the broader outlook is supported by steady revenue generation and solid cash-flow characteristics, technical indicators suggest overbought conditions, and valuation concerns persist due to negative earnings. With no recent earnings-call commentary or major corporate events to factor in, these elements do not alter the overall assessment.

More about Microlise Group Holdings Ltd.

Microlise Group Plc provides transport and fleet management technologies designed to boost efficiency, enhance safety, and lower emissions across logistics and transport operations. Founded in 1982, the company serves over 2,500 customers worldwide and operates from its headquarters in Nottingham, UK, with satellite offices in France, Australia, and India. Microlise is listed on AIM and carries the London Stock Exchange’s Green Economy Mark.

Fusion Antibodies plc (LSE:FAB) has reported interim results showing narrower losses and increased investment in R&D for the first half of FY2026, even as revenue fell year-on-year. The company underscored notable progress on its OptiMAL® platform, including a successful validation study with the U.S. National Cancer Institute and the award of a U.S. patent. Preparations for the commercial rollout of OptiMAL® remain on schedule, supported by encouraging early feedback from potential customers and the prospect of building a scalable, licensing-led revenue stream. Fusion is positioning itself to benefit from an improving market backdrop and intends to broaden its offering with new libraries geared toward diagnostic and veterinary applications.

The company’s outlook continues to be weighed down by financial strain and soft technical indicators. Persistent losses, tight cash flow, and negative profitability remain key challenges, while bearish trading signals point to continued downside risk. Valuation metrics reflect these pressures, contributing to a cautious overall assessment.

More about Fusion Antibodies Plc

Fusion Antibodies plc is a Northern Ireland–based Contract Research Organisation specializing in antibody discovery, engineering, and expression services for human and veterinary therapeutics as well as diagnostic applications. Its capabilities span discovery, development, optimization, characterization, and small-scale production, along with antigen design, expression, purification, and sequencing. The company has completed numerous humanization projects for leading global pharmaceutical firms and is focused on accelerating the antibody-driven drug discovery pipeline.

Upland Resources Limited (LSE:UPL) has announced a new strategic partnership with Lost Soldier Oil and Gas II Master Series LLC, marking an important step forward in the company’s growth strategy. The arrangement includes a bilateral investment valued at roughly $8.6 million, strengthening Upland’s financial position while adding technical depth to its operations. Through the partnership, Upland will gain direct participation in the Wild Mustang Federal Unit—considered one of the largest unconventional gas discoveries in the western United States—opening the door to both near-term production revenues and longer-term royalty income. Management expects the agreement to accelerate project timelines, improve operational efficiency, and create meaningful value for shareholders.

More about Upland Resources

Upland Resources Limited operates within the energy sector, focusing on the exploration and development of oil and gas assets. The company is active across Southeast Asia, where it targets the advancement of high-pressure gas fields and other unconventional resource opportunities.

Ondo InsurTech Plc (LSE:ONDO) is broadening its collaboration with Nationwide, extending the rollout of its LeakBot technology to a total of 26 U.S. states. The expansion builds on earlier deployments across 16 states, where LeakBot demonstrated strong effectiveness in reducing water damage incidents while maintaining high levels of customer satisfaction. The move further embeds LeakBot within Nationwide’s smart home ecosystem, offering homeowners more comprehensive protection against costly water-related losses.

Ondo’s broader outlook continues to be shaped by financial pressures, including persistent losses and elevated leverage. While technical signals point to a largely neutral trend, valuation metrics underscore the company’s ongoing financial hurdles.

More about Ondo InsurTech Plc

Ondo InsurTech Plc specializes in claims-prevention solutions for the home insurance sector, anchored by its patented LeakBot device—a self-install sensor designed to detect hidden water leaks before they escalate. The company works with 26 insurance partners across the U.S. and Europe and has been awarded the London Stock Exchange Green Economy Mark for its environmental contribution.

Powerhouse Energy Group Plc’s (LSE:PHE) engineering subsidiary, Engsolve, has reported a year of robust activity, marked by the completion of several major assignments and the securing of new work across hydrogen, bio-methanol, aluminium recycling, and carbon-capture technologies. The breadth of projects has prompted the company to scale up its team, positioning Engsolve for a solid start to 2026 and reinforcing its reputation as a growing provider of engineering and clean-energy solutions.

Powerhouse Energy’s overall outlook remains constrained by ongoing financial weakness and unfavourable technical trends. Persistent losses, negative profitability metrics, and bearish momentum continue to weigh heavily on valuation, underscored by a negative P/E ratio and the absence of dividend support.

More about Powerhouse Energy

Powerhouse Energy Group Plc has developed proprietary technology that converts waste plastic, end-of-life tyres, and other waste materials into syngas—a versatile feedstock used to generate hydrogen, electricity, heat, and other industrial outputs. The process is designed to be cost-effective, efficient, and environmentally responsible, suitable for deployment at both industrial and community scales. The company also owns Engsolve Ltd, a revenue-generating engineering services provider focused on advancing new technologies and clean-energy solutions.

Trellus Health PLC (LSE:TRLS) has secured a $600,000 unsecured loan from major shareholder Icahn School of Medicine at Mount Sinai, providing additional liquidity to support its commercial initiatives and extending its cash runway through January 2026. The facility carries no interest for the first six months and is intended to help the company deepen its engagement with pharmaceutical partners and contract research organizations. Trellus has recently signed agreements with two global CROs, with clinical trial implementations targeted before the end of the year.

More about Trellus Health PLC

Trellus Health PLC is a healthcare innovator delivering value-based solutions for individuals managing chronic conditions. Its flagship platform, Trellus Elevate®, integrates data analytics with personalized resilience-building programs, initially focused on gastrointestinal diseases such as IBD. The company also offers Trellus TrialSet™, a tool designed to enhance clinical trial support and patient engagement for pharmaceutical collaborators.

Walker Crips Group plc (LSE:WCW) has accepted a recommended all-cash offer from PhillipCapital UK Ltd, which plans to acquire the company’s entire issued share capital. The deal places an equity value of roughly £5.96 million on Walker Crips, marking a substantial premium to its recent trading levels. The Independent Directors have unanimously backed the transaction, citing the potential for strengthened capabilities and improved competitiveness within the UK wealth management market, even as the firm navigates regulatory pressures and liquidity constraints.

Walker Crips continues to grapple with notable financial and operational headwinds, including falling revenues, weak cash flow, and persistent negative sentiment reflected in bearish technical trends. Its negative P/E ratio underscores ongoing valuation challenges. Restoring operational efficiency and stabilizing cash generation remain critical priorities for the company’s near-term financial recovery.

More about Walker Crips

Walker Crips Group plc is a long-standing participant in the UK wealth management sector, offering investment management services and structured financial products. The firm is recognized for its established brand and loyal client base, built over decades of market presence.

Alien Metals Ltd (LSE:UFO), working alongside joint-venture partner West Coast Silver Limited, has reported encouraging findings from the Phase 2 diamond drilling campaign at the Elizabeth Hill Silver Project in Western Australia. The latest holes encountered new zones of shallow, high-grade silver outside the areas historically mined, pointing to a larger mineralized system than previously understood. These results add momentum to the project’s development prospects and further solidify Alien Metals’ standing within the exploration and mining sector.

More about Alien Metals Ltd

Alien Metals Ltd is an exploration and development company listed on the AIM market of the London Stock Exchange. Its primary focus is advancing a direct-shipping iron ore operation at the Hancock project in Western Australia. The company also maintains exposure to PGM and gold assets, along with an expanding portfolio of silver exploration projects.